Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2018, Article ID 1319628, 7 pages
https://doi.org/10.1155/2018/1319628
Clinical Study

Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients

1Eye and Ear Hospital International, Naccache, Lebanon
2Holy Spirit University, Kaslik, Lebanon
3Saint Joseph University, Beirut, Lebanon

Correspondence should be addressed to Georges Georges Azar; moc.liamtoh@razasegroeg

Received 6 August 2017; Revised 7 November 2017; Accepted 3 December 2017; Published 7 March 2018

Academic Editor: Sotiria Palioura

Copyright © 2018 Wissam Georges El Hajj Moussa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. A. Quigley and A. T. Broman, “The number of people with glaucoma worldwide in 2010 and 2020,” British Journal of Ophthalmology, vol. 90, no. 3, pp. 262–267, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Cristina Leske, A. Heijl, M. Hussein et al., “Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Treatment Trial,” Archives of Ophthalmology, vol. 121, no. 1, pp. 48–56, 2003. View at Publisher · View at Google Scholar
  3. A. J. Lee and P. McCluskey, “Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension,” Clinical Ophthalmology, vol. 4, pp. 741–764, 2010. View at Publisher · View at Google Scholar
  4. C. Baudouin, “Side effects of antiglaucomatous drugs on the ocular surface,” Current Opinion in Ophthalmology, vol. 7, no. 2, pp. 80–86, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Vaede, C. Baudouin, J.-M. Warnet, and F. Brignole-Baudouin, “Preservatives in eye drops: toward awareness of their toxicity,” Journal Français d'Ophtalmologie, vol. 33, no. 7, pp. 505–524, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. G. C. M. Rossi, L. Scudeller, T. Rolle, G. M. Pasinetti, and P. E. Bianchi, “From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability,” Expert Opinion on Drug Safety, vol. 14, no. 5, pp. 619–623, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. C. B. Camras and the United States Latanoprost Study Group, “Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States,” Ophthalmology, vol. 103, no. 1, pp. 138–147, 1996. View at Publisher · View at Google Scholar
  8. R. L. Fellman, E. Kenneth Sullivan, M. Ratliff et al., “Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial,” Ophthalmology, vol. 109, no. 5, pp. 998–1008, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. S. M. Whitcup, L. B. Cantor, A. M. VanDenburgh, and K. Chen, “A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension,” British Journal of Ophthalmology, vol. 87, no. 1, pp. 57–62, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Chabi, R. Varma, J. C. Tsai et al., “Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension,” American Journal of Ophthalmology, vol. 153, no. 6, pp. 1187–1196, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Orzalesi, L. Rossetti, A. Bottoli, and P. Fogagnolo, “Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension,” Ophthalmology, vol. 113, no. 2, pp. 239–246, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Alagöz, K. Gürel, A. Bayer, D. Serin, S. Çelebi, and Ş. Kükner, “A comparative study of bimatoprost and travoprost: effect on intraocular pressure and ocular circulation in newly diagnosed glaucoma patients,” Ophthalmologica, vol. 222, no. 2, pp. 88–95, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Chander, H. Kapoor, and S. Thomas, “Comparison of the efficacy and safety of bimatoprost (0.03 %) and travoprost (0.004 %) in patients with primary open angle glaucoma,” Nepalese Journal of Ophthalmology, vol. 5, no. 1, pp. 75–80, 2013. View at Publisher · View at Google Scholar
  14. D. Schnober, G. Hofmann, H. Maier, M. L. Scherzer, A. B. Ogundele, and M. C. Jasek, “Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension,” Clinical Ophthalmology, vol. 4, pp. 1459–1463, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Holmstrom, P. Buchholz, J. Walt, J. Wickstrom, and M. Aagren, “Analytic review of Bimatoprost, latanoprost and travoprost in primary open angle glaucoma,” Current Medical Research and Opinion, vol. 21, no. 11, pp. 1875–1883, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Aptel, M. Cucherat, and P. Denis, “Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials,” Journal of Glaucoma, vol. 17, no. 8, pp. 667–673, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. J. W. Cheng and R. L. Wei, “Meta-analysis of 13 randomized controlled trials comparing Bimatoprost with latanoprost in patients with elevated intraocular pressure,” Clinical Therapeutics, vol. 30, no. 4, pp. 622–632, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Denis, A. Lafuma, B. Khoshnood, V. Mimaud, and G. Berdeaux, “A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy,” Current Medical Research and Opinion, vol. 23, no. 3, pp. 601–608, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. O. Eyawo, J. Nachega, P. Lefebvre et al., “Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis,” Clinical Ophthalmology, vol. 3, pp. 447–456, 2009. View at Publisher · View at Google Scholar
  20. N. Li, X. M. Chen, Y. Zhou, M. L. Wei, and X. Yao, “Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials,” Clinical & Experimental Ophthalmology, vol. 34, no. 8, pp. 755–764, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Orme, S. Collins, H. Dakin, S. Kelly, and J. Loftus, “Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension,” Current Medical Research and Opinion, vol. 26, no. 3, pp. 511–528, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Ranno, M. Sacchi, C. Brancato, D. Gilardi, A. Lembo, and P. Nucci, “A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients,” Scientific World Journal, vol. 2012, article 804730, 6 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Lin, Y. J. Zhao, P. T. K. Chew et al., “Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension,” The Annals of Pharmacotherapy, vol. 48, no. 12, pp. 1585–1593, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Hommer and F. Kimmich, “Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost,” Clinical Ophthalmology, vol. 5, pp. 623–631, 2011. View at Publisher · View at Google Scholar
  25. E. Brasnu, F. Brignole-Baudouin, L. Riancho, J.-M. Guenoun, J.-M. Warnet, and C. Baudouin, “In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line,” Current Eye Research, vol. 33, no. 4, pp. 303–312, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Liang, C. Baudouin, A. Pauly, and F. Brignole-Baudouin, “Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride,” The British Journal of Ophthalmology, vol. 92, no. 9, pp. 1275–1282, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Y. Kahook and R. Noecker, “Quantitative analysis of conjunctival goblet cells after chronic application of topical drops,” Advances in Therapy, vol. 25, no. 8, pp. 743–751, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. J. H. Kim, E. J. Kim, Y. H. Kim et al., “In vivo effects of preservative-free and preserved prostaglandin analogs: mouse ocular surface study,” Korean Journal of Ophthalmology, vol. 29, no. 4, pp. 270–279, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Wand, C. M. Gilbert, and T. J. Liesegang, “Latanoprost and herpes simplex keratitis,” American Journal of Ophthalmology, vol. 127, no. 5, pp. 602–604, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Deai, M. Fukuda, T. Hibino, S. Higaki, K. Hayashi, and Y. Shimomura, “Herpes simplex virus genome quantification in two patients who developed herpetic epithelial keratitis during treatment with antiglaucoma medications,” Cornea, vol. 23, no. 2, pp. 125–128, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Ekatomatosis, “Herpes simplex dendritic keratitis after treatment with latanoprost for primary open angle glaucoma,” The British Journal of Ophthalmology, vol. 85, no. 8, pp. 1007a–11007, 2001. View at Publisher · View at Google Scholar